Corporate strategies and tactics for more effective drug development.
February 3, 2010
By:William Looney
California's biotech industry takes its own pulse in a new survey that tracks how the state is doing in serving as the nation's medicine cabinet and avatar of drug innovation.
 |
January 20, 2010
By:George Koroneos, Online Content & News Editor
GlaxoSmithKline announced that it would open up its library of prospective molecules and investigational vaccines. This move gives researchers free access to study experimental treatments for illnesses that plague the world's poorest countries.
|
December 16, 2009
By:George Koroneos
It's been a tough week for clinical trials: One drug got canned and another was re-tuned in the wake of failed end points and patient deaths.
|
 | December 8, 2009
By:Alexandra Kibble
Alexandra Kibble of Thomson Reuters identifies the products and therapy areas to watch next year.
|
December 1, 2009
By:Walter Armstrong
As the old orthodoxy shatters, pharma must stand firm or leave the field.
|
December 1, 2009
By:Ron Feemster
Our sixth annual pipeline report details 44 drugs that industry will be talking about in 2010.
|
November 18, 2009
By:Emmanuel Le Poul
Allosteric modulators are an emerging class of orally available small molecule drugs that may have multiple advantages compared to traditional drugs.
|
November 18, 2009
By:Andrew Sheivachman
Dubbed as the 'female Viagra,' Boehringer Ingelheim's filbanserin represents an unprecedented step forward in treating female sexual dysfunction.
|
 | November 4, 2009
By:Bassil Dahiyat
As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
The New Health is the fast-morphing world of biopharma: emerging science, changing technology, rising costs, global regulations. The New Health needs an ally. More at www.quintiles.com/newhealth.
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA